Keywords
How to Cite
Abstract
Metformin (MF) belongs to the most popular andidiabetic medicines and is considered to possess a selective antineoplastic action. This selectivity at least partly may be explained by the certain features of MF pharmacogenetics. More than 150 postmenopausal females divided into 4 groups (cancer +diabetes type 2 (DM2); cancer without DM2; DM2 without cancer, and healthy) were studied. Genetic polymorphisms of the two groups of genes — entitled on the basis of the relation to potential MF effect as a ‘standard’ (S) or ‘associated’ (A) — were under investigation. Among S-markers a most informative in regard of MF response prediction appeared to be polymorphisms of OCT1-R61C organic cation transporter protein 1 gene and serin/threonine kinase STK11. In the group of A-polymorphisms the GC genotype of oxidized lipoprotein receptor OLR1_G501C demonstrated tendency to the combination with ‘MF-positive’ variant of OCT1_R61C. The carriers of the latter were characterized with insulin resistance while carriers of STK11 variants — with lower blood estradiol level. Postmenopausal diabetics with as well as without cancer, differ in genetic markers of potential response to metformin less than they differ from cancer patients without DM2.References
Берштейн Л.М. Бигуаниды: экспансия в практическую онкологию (прошлое и настоящее). СПб: Эскулап. 2010. — С. 143.
Берштейн Л.М. Диабет, ожирение и онкологическая заболеваемость: риски и антириски // Сахарный диабет. — 2012. — N 4. — С. 81-88.
Дильман В.М., Берштейн Л.М., Цырлина Е.В. и др. О коррекции эндокринно-обменных нарушений у онкологических больных. Эффект бигуанидов (фенформина и адебита), мисклерона и дифенина // Вопр. онкол. — 1975. — Т. 21 (11). — С. 33-39.
Сунцов Ю.И., Болотская Л.Л., Маслова О.В., Казаков И.В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации // Сахарный диабет. — 2011. — N 1. — С. 15-18.
Улыбина Ю.М., Имянитов Е.Н., Васильев Д.А., Берштейн Л.М. Полиморфные маркеры генов, определяющих нарушения жироуглеводного обмена и инсулинорезистентность, у онкологических больных // Мол. биол. — 2008. — T 42 (6). — C. 947-956.
Anisimov V.N. Metformin for aging and cancer prevention //Aging (Albany NY). — 2010. — Vol. 2 (11). — P 760774.
Becker M.L., Visser L.E., van Schaik R.H. et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus // Pharmacogenomics J. — 2009. — Vol. 9 (4). — P. 242-247.
Berstein L.M. Metformin in obesity, cancer and aging: addressing controversies // Aging (Albany NY). — 2012. — Vol. 4 (5). — P. 320-329.
Christensen M.M, Brasch-Andersen C., Green H. et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c // Pharmacogenet. Genomics. — 2011. — Vol. 21 (12). — P837-850.
Currie C.J., Poole C.D., Evans M. et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes // J. Clin. Endocrinol. Metab. 2013. — Vol. 98 (2). — P. 668-677.
Dilman V.M., Berstein L.M., Yevtushenko T.P et al. Preliminary evidence on methabolic rehabilitation of cancer patients // Arch.Geschwulstf. — 1988. — Vol. 58 (3). — P. 175-183.
Giovannucci E., Harlan D.M., Archer M.C. et al. Diabetes and cancer: a consensus report // Diabetes Care. 2010. — Vol. 33 (7). — P. 1674-1685.
GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K. Bellenguez C, Spencer CC. et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes // Nat. Genet. — 2011. — Vol. 43 (2). — P. 117-120.
Goodwin PJ, Stambolic V, Lemieux J et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anticancer agents // Breast Cancer Res Treat. — 2011. — Vol. 126 (1). — P. 215-120.
Graham G.G., Punt J., Arora M. et al. Clinical pharmacokinetics of metformin // Clin Pharmacokinet. 2011. — Vol. 50 (2). — P. 81-98.
Hardie D.G. Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection // Cold Spring Harb Symp Quant Biol. — 2011. — Vol. 76. — P. 155-164.
Lam D.W., LeRoith D. The worldwide diabetes epidemic // Curr. Opin. Endocrinol. Diabetes Obes. — 2012. — Vol. 19 (2). — P. 93-96.
Le T.N., Nestler J.E., Strauss J.F. 3rd, Wickham E.P Sex hormone-binding globulin and type 2 diabetes mellitus // Trends Endocrinol. Metab. — 2012. — Vol. 23 (1). — P. 32-40.
Legro R.S., Barnhart H.X., Schlaff W.D. et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93 (3). — P. 792-800.
Loh K.C., Leow M.K. Current therapeutic strategies for type 2 diabetes mellitus // Ann Acad Med. (Singapore) — 2002. — Vol. 31 (6). — P. 722-730.
Matthews D.R., Hosker J.P, Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. — 28 (7). — Р. 412-419.
Ong C.R., Molyneaux L.M., Constantino M.I. et al. Longterm efficacy of metformin therapy in nonobese individuals with type 2 diabetes // Diabetes Care. — 2006. — Vol. 29 (10). — P. 2361-2364.
Pacanowski M.A., Hopley C.W., Aquilante CL.Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms // Expert Opin Drug Metab Toxicol.- 2008. — Vol. 4 (5). — P. 529-544.
Pollak M.N. Investigating metformin for cancer prevention and treatment: the end of the beginning // Cancer Discov. — 2012. — Vol. 2 (9). — P. 778-790.
Quinn B.J., Kitagawa H., Memmott R.M. et al. Repositioning metformin for cancer prevention and treatment // Trends Endocrinol Metab. — 2013. — Vol. 24 (9). — P. 469-480.
Rice S., Elia A., Jawad Z. et al. Metformin Inhibits Follicle-Stimulating Hormone (FSH) Action in Human Granulosa Cells: Relevance to Polycystic Ovary Syndrome // J Clin Endocrinol Metab. — 2013. — Vol. 98 (9). — Р1491-1500.
Shu Y, Sheardown S.A., Brown C. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action // J Clin Invest. — 2007. — Vol. 117 (5). — P. 1422-1431.
Thameem F., Puppala S., Lehman D.M. et al. The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans // Hum. Hered. — 2010. — Vol. 70 (2). — P. 97-101
Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters // Ann Med. 2012. — Vol. 44 (2). — P. 119-129
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...